Free Trial
NASDAQ:TLSI

TriSalus Life Sciences (TLSI) Stock Price, News & Analysis

TriSalus Life Sciences logo
$4.01
+0.04 (+1.01%)
(As of 11/1/2024 ET)

About TriSalus Life Sciences Stock (NASDAQ:TLSI)

Key Stats

Today's Range
$3.83
$4.08
50-Day Range
$3.97
$5.78
52-Week Range
$3.32
$10.42
Volume
4,946 shs
Average Volume
38,732 shs
Market Capitalization
$117.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50
Consensus Rating
Buy

Company Overview

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

TriSalus Life Sciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
70th Percentile Overall Score

TLSI MarketRank™: 

TriSalus Life Sciences scored higher than 70% of companies evaluated by MarketBeat, and ranked 337th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    TriSalus Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    TriSalus Life Sciences has only been the subject of 3 research reports in the past 90 days.

  • Read more about TriSalus Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for TriSalus Life Sciences are expected to grow in the coming year, from ($1.51) to ($1.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of TriSalus Life Sciences is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of TriSalus Life Sciences is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about TriSalus Life Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    1.40% of the float of TriSalus Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    TriSalus Life Sciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in TriSalus Life Sciences has recently increased by 21.29%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    TriSalus Life Sciences does not currently pay a dividend.

  • Dividend Growth

    TriSalus Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.40% of the float of TriSalus Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    TriSalus Life Sciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in TriSalus Life Sciences has recently increased by 21.29%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    TriSalus Life Sciences has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for TriSalus Life Sciences this week, compared to 1 article on an average week.
  • Search Interest

    3 people have searched for TLSI on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, TriSalus Life Sciences insiders have bought 127,808.00% more of their company's stock than they have sold. Specifically, they have bought $63,954.00 in company stock and sold $50.00 in company stock.

  • Percentage Held by Insiders

    32.80% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 2.58% of the stock of TriSalus Life Sciences is held by institutions.

  • Read more about TriSalus Life Sciences' insider trading history.
Receive TLSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

TLSI Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
TriSalus Life Sciences Inc.
See More Headlines

TLSI Stock Analysis - Frequently Asked Questions

TriSalus Life Sciences' stock was trading at $8.45 at the beginning of 2024. Since then, TLSI shares have decreased by 52.5% and is now trading at $4.01.
View the best growth stocks for 2024 here
.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) issued its earnings results on Wednesday, August, 14th. The company reported ($0.21) earnings per share for the quarter. The firm earned $7.36 million during the quarter.

Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that TriSalus Life Sciences investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Merck & Co., Inc. (MRK), TJX Companies (TJX), Abacus Health Products (ABAHF) and Airbnb (ABNB).

Company Calendar

Last Earnings
8/14/2024
Today
11/02/2024
Next Earnings (Confirmed)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:TLSI
Previous Symbol
NASDAQ:TLSI
Fax
N/A
Employees
106
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.50
High Stock Price Target
$16.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+211.7%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

Net Income
$-59,040,000.00
Net Margins
-219.71%
Pretax Margin
-219.67%

Debt

Sales & Book Value

Annual Sales
$18.51 million
Book Value
($0.98) per share

Miscellaneous

Free Float
19,697,000
Market Cap
$117.53 million
Optionable
Not Optionable
Beta
0.47
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:TLSI) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners